Clinical Trials Detail

Reflections - A phase 3 randomized double-blind study of PF-05280014 plus paclitaxel versus trastuzumab plus paclitaxel for the first-line treatment of patients with HER2-positive metastatic breast cancer.



HER2 positive metastatic breast cancer.


This study will compare the use of a currently marketed drug named trastuzumab to a drug that has been developed to be similar to trastuzumab (called a biosimilar drug). Each participant will be randomized (like tossing a coin) to receive either the trastuzumab or the biosimilar drug. Each drug will be given in combination with another drug called paclitaxel. Neither the participant nor the doctor will know which drug the participant is receiving. The study will compare the effectiveness and safety of the drugs, as well as how the body uses the drugs.


  • To compare the response rate in patients with metastatic HER2-positive breast cancer who receive study drug to those who receive trastuzumab in combination with paclitaxel.

Participating Physician Clinics

  • Boston Baskin Cancer Foundation – East Memphis, Bartlett, Southaven

Clinical Trial Categories

  • Breast Cancer
Pfizer, Inc
How to Participate

Partial Inclusion Criteria

  • Diagnosis of HER2+ metastatic breast cancer.
  • Determination of HER2+ status using a sponsor-approved analytical test.
  • At least one measurable lesion (defined by RECIST 1.1) outside prior radiation fields.
  • No prior systemic therapy for metastatic disease (except endocrine therapy) and no relapse within one year of last dose of previous adjuvant (including neoadjuvant) treatment (except endocrine therapy).

For the current eligibility status of this clinical study, referring physicians may call the Baptist referral line at 901-227-DOCS (3627).